Showing 4 posts of 4 posts found.


Top Ten most popular articles on this week

July 26, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten

At the end of a week that could certainly be called “eventful” here in the UK – one that saw …


FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …


Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …


Reaction mixed to Biohaven’s migraine drug results

March 27, 2018
Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical

Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …

Latest content